Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Dec 10:14:5293-5301.
doi: 10.2147/IDR.S301153. eCollection 2021.

Management of Multidrug Resistant Infections in Lung Transplant Recipients with Cystic Fibrosis

Jaideep Vazirani  1 , Thomas Crowhurst  1   2 , C Orla Morrissey  3 , Gregory I Snell  1
Affiliations
Review

Management of Multidrug Resistant Infections in Lung Transplant Recipients with Cystic Fibrosis

Jaideep Vazirani et al. Infect Drug Resist. .

Abstract

Cystic fibrosis (CF) is an inherited multisystem disease characterised by bronchiectasis and chronic respiratory infections which eventually cause end stage lung disease. Lung transplantation (LTx) is a well-established treatment option for patients with CF-associated lung disease, improving survival and quality of life. Navigating recurrent infections in the setting of LTx is often difficult, where immune suppression must be balanced against the constant threat of infection. Sepsis/infections are one of the major contributors to post-LTx mortality and multiresistant organisms (eg, Burkholderia cepacia complex, Mycobacterium abscessus complex, Scedosporium spp. and Lomentospora spp.) pose a significant threat to survival. This review will summarize current and novel therapies to assist with the management of multiresistant bacterial, mycobacterial, viral and fungal infections which threaten the CF LTx cohort.

Keywords: cystic fibrosis; lung transplant; multidrug resistant infection.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

References

    1. Cutting GR. MODIFIER GENETICS: cystic Fibrosis. Annu Rev Genom Hum Genet. 2005;6(1):237–260. doi: 10.1146/annurev.genom.6.080604.162254 - DOI - PubMed
    1. Ratjen F, Bell SC, Rowe SM, Goss CH, Quittner AL, Bush A. Cystic fibrosis. Nat Rev Dis Primers. 2015;1(1):15010. doi: 10.1038/nrdp.2015.10 - DOI - PMC - PubMed
    1. Keogh RH, Szczesniak R, Taylor-Robinson D, Bilton D. Up-to-date and projected estimates of survival for people with cystic fibrosis using baseline characteristics: a longitudinal study using UK registry data. J Cyst Fibros. 2018;17(2):218–227. doi: 10.1016/j.jcf2017.11.019 - DOI - PMC - PubMed
    1. Nettie Burke SA. The Australian cystic fibrosis data registry annual report, 2019. Monash University, Department of Epidemiology and Preventive Medicine; 2021. Available from: https://www.cysticfibrosis.org.au/getmedia/bcab56d9-5bbe-4b19-9486-85a0a.... Accessed June 15, 2021.
    1. Thabut G, Christie JD, Mal H, et al. Survival benefit of lung transplant for cystic fibrosis since lung allocation score implementation. Am J Respir Crit Care Med. 2013;187(12):1335–1340. doi: 10.1164/rccm.201303-0429OC - DOI - PMC - PubMed